Debanjana Chatterjee
Stock Analyst at Jones Trading
(2.23)
# 2,661
Out of 4,876 analysts
10
Total ratings
44.44%
Success rate
11.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBPH Theravance Biopharma | Initiates: Buy | $24 | $10.73 | +123.67% | 1 | Jun 17, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $15 → $27 | $8.70 | +210.34% | 2 | Jun 6, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Buy | $39 | $25.21 | +54.70% | 1 | Apr 28, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | $30 | $11.50 | +160.87% | 2 | Mar 26, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Buy | $23 | $4.01 | +473.57% | 1 | Mar 13, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Hold | n/a | $16.03 | - | 1 | Dec 11, 2024 | |
| PHVS Pharvaris | Initiates: Buy | $46 | $17.44 | +163.76% | 1 | Sep 19, 2024 | |
| NTLA Intellia Therapeutics | Initiates: Buy | $41 | $9.61 | +326.64% | 1 | Sep 17, 2024 |
Theravance Biopharma
Jun 17, 2025
Initiates: Buy
Price Target: $24
Current: $10.73
Upside: +123.67%
Sagimet Biosciences
Jun 6, 2025
Maintains: Buy
Price Target: $15 → $27
Current: $8.70
Upside: +210.34%
Tvardi Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $39
Current: $25.21
Upside: +54.70%
KalVista Pharmaceuticals
Mar 26, 2025
Maintains: Buy
Price Target: $30
Current: $11.50
Upside: +160.87%
Contineum Therapeutics
Mar 13, 2025
Initiates: Buy
Price Target: $23
Current: $4.01
Upside: +473.57%
Spyre Therapeutics
Dec 11, 2024
Initiates: Hold
Price Target: n/a
Current: $16.03
Upside: -
Pharvaris
Sep 19, 2024
Initiates: Buy
Price Target: $46
Current: $17.44
Upside: +163.76%
Intellia Therapeutics
Sep 17, 2024
Initiates: Buy
Price Target: $41
Current: $9.61
Upside: +326.64%